The University of Chicago Header Logo

Connection

Walter M. Stadler to Carcinoma, Renal Cell

Back to Details
This is a "connection" page, showing publications Walter M. Stadler has written about Carcinoma, Renal Cell.
Walter M. Stadler
Connection Strength
13.350
Carcinoma, Renal Cell
  1. Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. Clin Genitourin Cancer. 2022 12; 20(6):510-514.
    View in: PubMed
    Score: 0.605
  2. Maturing of renal cancer therapeutics. J Clin Oncol. 2014 Mar 10; 32(8):722-4.
    View in: PubMed
    Score: 0.340
  3. Predictive markers in advanced renal cell carcinoma. Semin Oncol. 2013 Aug; 40(4):459-64.
    View in: PubMed
    Score: 0.328
  4. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med. 2013 Aug; 2(4):545-52.
    View in: PubMed
    Score: 0.326
  5. Renal cancer therapeutics: now what? Oncology (Williston Park). 2012 Mar; 26(3):301, 304.
    View in: PubMed
    Score: 0.297
  6. Pazopanib in renal cell carcinoma. Clin Cancer Res. 2010 Dec 15; 16(24):5923-7.
    View in: PubMed
    Score: 0.271
  7. Bevacizumab and everolimus in renal cancer: a rational way forward. J Clin Oncol. 2010 Nov 20; 28(33):e692-3; author reply e694.
    View in: PubMed
    Score: 0.270
  8. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010 Mar 01; 116(5):1272-80.
    View in: PubMed
    Score: 0.259
  9. Effective therapy for metastatic renal cancer, whither to now. J Clin Oncol. 2009 Aug 01; 27(22):3573-4.
    View in: PubMed
    Score: 0.245
  10. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
    View in: PubMed
    Score: 0.234
  11. Angiogenesis inhibition in non-clear cell renal cancer. Clin Adv Hematol Oncol. 2008 Jul; 6(7):507-9.
    View in: PubMed
    Score: 0.230
  12. A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer. Clin Genitourin Cancer. 2008 Mar; 6(1):21-4.
    View in: PubMed
    Score: 0.225
  13. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):689-94.
    View in: PubMed
    Score: 0.214
  14. Prognostic factors in localized renal cell cancer. BJU Int. 2007 May; 99(5 Pt B):1212-6.
    View in: PubMed
    Score: 0.212
  15. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther. 2007 Apr; 6(4):490-3.
    View in: PubMed
    Score: 0.211
  16. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer. 2006 Sep 15; 107(6):1273-9.
    View in: PubMed
    Score: 0.203
  17. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006 Jun; 5(1):57-60.
    View in: PubMed
    Score: 0.199
  18. New therapeutic options for renal cell carcinoma. Clin Adv Hematol Oncol. 2006 Jun; 4(6):429-30.
    View in: PubMed
    Score: 0.199
  19. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. Clin Genitourin Cancer. 2006 Mar; 4(4):275-80.
    View in: PubMed
    Score: 0.196
  20. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer. 2005 Dec 01; 104(11):2323-33.
    View in: PubMed
    Score: 0.193
  21. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 01; 23(16):3726-32.
    View in: PubMed
    Score: 0.186
  22. Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. Curr Oncol Rep. 2005 Mar; 7(2):116-22.
    View in: PubMed
    Score: 0.183
  23. Therapeutic options for variant renal cancer: a true orphan disease. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6393S-6S.
    View in: PubMed
    Score: 0.177
  24. Cytotoxic chemotherapy for metastatic renal cell carcinoma. Urologe A. 2004 Sep; 43 Suppl 3:S145-6.
    View in: PubMed
    Score: 0.177
  25. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024 Aug 22; 391(8):710-721.
    View in: PubMed
    Score: 0.176
  26. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol. 2004 Jan 01; 22(1):115-9.
    View in: PubMed
    Score: 0.169
  27. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 2003 Oct; 170(4 Pt 1):1141-5.
    View in: PubMed
    Score: 0.166
  28. The role of systemic chemotherapy in the treatment of kidney cancer. Cancer Treat Res. 2003; 116:173-82.
    View in: PubMed
    Score: 0.157
  29. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002 Oct 15; 95(8):1629-36.
    View in: PubMed
    Score: 0.155
  30. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 10 01; 8(10):1411-1418.
    View in: PubMed
    Score: 0.155
  31. A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol. 2002 Aug; 50(2):160-2.
    View in: PubMed
    Score: 0.152
  32. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer. 2002 May 15; 94(10):2602-9.
    View in: PubMed
    Score: 0.151
  33. Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother. 2002 May-Jun; 25(3):269-77.
    View in: PubMed
    Score: 0.150
  34. NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases. Am J Surg Pathol. 2022 05 01; 46(5):617-627.
    View in: PubMed
    Score: 0.150
  35. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2022 02; 6:e2100448.
    View in: PubMed
    Score: 0.148
  36. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol. 2002 Jan; 13(1):116-20.
    View in: PubMed
    Score: 0.147
  37. A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clin Genitourin Cancer. 2022 02; 20(1):1-10.
    View in: PubMed
    Score: 0.142
  38. Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer. 2021 07 01; 127(13):2204-2212.
    View in: PubMed
    Score: 0.139
  39. Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. Eur Urol. 2021 05; 79(5):665-673.
    View in: PubMed
    Score: 0.139
  40. Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 06 15; 27(12):3317-3328.
    View in: PubMed
    Score: 0.138
  41. Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case. Pathology. 2021 Oct; 53(6):790-793.
    View in: PubMed
    Score: 0.138
  42. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). J Clin Oncol. 2020 12 20; 38(36):4240-4248.
    View in: PubMed
    Score: 0.135
  43. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000 Jun; 18(12):2419-26.
    View in: PubMed
    Score: 0.132
  44. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials. Cancer. 2000 Mar 15; 88(6):1317-24.
    View in: PubMed
    Score: 0.130
  45. Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2020 06 01; 26(11):2506-2514.
    View in: PubMed
    Score: 0.129
  46. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol. 2000 Jan; 18(2):371-5.
    View in: PubMed
    Score: 0.128
  47. Renal cancer immunotherapy: a ray of hope or regression to the mean? Cancer Invest. 2000; 18(5):490-1.
    View in: PubMed
    Score: 0.128
  48. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol. 1999 Aug; 17(8):2541-5.
    View in: PubMed
    Score: 0.124
  49. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 06 15; 393(10189):2404-2415.
    View in: PubMed
    Score: 0.122
  50. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695.
    View in: PubMed
    Score: 0.122
  51. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. 2019 03 11; 7(1):66.
    View in: PubMed
    Score: 0.121
  52. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019 04; 20(4):581-590.
    View in: PubMed
    Score: 0.121
  53. Cytokine therapy in metastatic renal cancer. N Engl J Med. 1998 Sep 17; 339(12):849; author reply 850-1.
    View in: PubMed
    Score: 0.117
  54. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 06; 24(6):749-757.
    View in: PubMed
    Score: 0.115
  55. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol. 1998 May; 16(5):1820-5.
    View in: PubMed
    Score: 0.114
  56. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Dec 01; 123(23):4566-4573.
    View in: PubMed
    Score: 0.109
  57. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 Nov 15; 22(22):5461-5471.
    View in: PubMed
    Score: 0.099
  58. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Target Oncol. 2016 Apr; 11(2):229-34.
    View in: PubMed
    Score: 0.099
  59. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14; 387(10032):2008-16.
    View in: PubMed
    Score: 0.098
  60. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016 Mar; 17(3):378-388.
    View in: PubMed
    Score: 0.097
  61. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol. 2016 Jan; 77(1):155-62.
    View in: PubMed
    Score: 0.096
  62. A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma. Cancer. 1995 Nov 01; 76(9):1629-33.
    View in: PubMed
    Score: 0.096
  63. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer. 2015 Jun 01; 121(11):1906.
    View in: PubMed
    Score: 0.091
  64. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin Oncol. 1995 Feb; 22(1):67-73.
    View in: PubMed
    Score: 0.091
  65. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer. 2014 Jun 01; 120(11):1647-55.
    View in: PubMed
    Score: 0.085
  66. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013 Dec; 36(6):589-95.
    View in: PubMed
    Score: 0.084
  67. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer. 2014 Jan 01; 120(1):52-60.
    View in: PubMed
    Score: 0.083
  68. Human renal cancer carcinogenesis: a review of recent advances. Ann Oncol. 1993 Jun; 4(6):451-62.
    View in: PubMed
    Score: 0.081
  69. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013 May; 53(5):491-504.
    View in: PubMed
    Score: 0.080
  70. Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51.
    View in: PubMed
    Score: 0.079
  71. Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst. 1992 Dec 02; 84(23):1835-6.
    View in: PubMed
    Score: 0.078
  72. Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer. Cancer Chemother Pharmacol. 1992; 31(3):213-6.
    View in: PubMed
    Score: 0.073
  73. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. J Cancer Surviv. 2011 Sep; 5(3):255-62.
    View in: PubMed
    Score: 0.070
  74. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep; 108(5):679-86.
    View in: PubMed
    Score: 0.068
  75. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology. 2010; 78(5-6):340-7.
    View in: PubMed
    Score: 0.067
  76. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 01; 28(13):2137-43.
    View in: PubMed
    Score: 0.065
  77. Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nat Rev Urol. 2010 Feb; 7(2):110-4.
    View in: PubMed
    Score: 0.064
  78. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 20; 27(27):4462-8.
    View in: PubMed
    Score: 0.062
  79. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 Jul 10; 27(20):3312-8.
    View in: PubMed
    Score: 0.061
  80. Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer. 2009 Jan; 7(1):39-42.
    View in: PubMed
    Score: 0.060
  81. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008 Nov 20; 26(33):5422-8.
    View in: PubMed
    Score: 0.059
  82. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008 Aug 01; 26(22):3743-8.
    View in: PubMed
    Score: 0.058
  83. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer. 2008 Jul 01; 113(1):72-7.
    View in: PubMed
    Score: 0.058
  84. Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. Oncogene. 2007 Feb 26; 26(9):1346-50.
    View in: PubMed
    Score: 0.052
  85. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11; 356(2):125-34.
    View in: PubMed
    Score: 0.052
  86. Gene expression profiling in kidney cancer: combining differential expression and chromosomal and pathway analyses. Clin Genitourin Cancer. 2006 Dec; 5(3):227-31.
    View in: PubMed
    Score: 0.052
  87. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant. 2006 Jul; 12(7):778-85.
    View in: PubMed
    Score: 0.050
  88. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 01; 24(16):2505-12.
    View in: PubMed
    Score: 0.049
  89. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9.
    View in: PubMed
    Score: 0.049
  90. Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma. Invest New Drugs. 2005 Dec; 23(6):577-81.
    View in: PubMed
    Score: 0.048
  91. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005 Jul 01; 65(13):5628-37.
    View in: PubMed
    Score: 0.047
  92. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 2005 Feb; 35(3):253-60.
    View in: PubMed
    Score: 0.045
  93. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res. 2005 Feb 01; 11(3):1181-9.
    View in: PubMed
    Score: 0.045
  94. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004 Jul; 15(7):1109-14.
    View in: PubMed
    Score: 0.044
  95. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004 Mar 01; 22(5):909-18.
    View in: PubMed
    Score: 0.043
  96. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res. 2003 Sep 15; 63(18):6069-75.
    View in: PubMed
    Score: 0.041
  97. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002 Nov 15; 20(22):4478-84.
    View in: PubMed
    Score: 0.039
  98. Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J Urol. 2001 Apr; 165(4):1208-9.
    View in: PubMed
    Score: 0.035
  99. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs. 2001; 19(3):255-60.
    View in: PubMed
    Score: 0.034
  100. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res. 2000 Sep; 6(9):3400-5.
    View in: PubMed
    Score: 0.033
  101. Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial. Cancer. 1998 Apr 01; 82(7):1352-8.
    View in: PubMed
    Score: 0.028
  102. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience. Urology. 1996 Feb; 47(2):194-7.
    View in: PubMed
    Score: 0.024
  103. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
    View in: PubMed
    Score: 0.017
  104. Activities and accomplishments of the cancer and leukemia group B genitourinary committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3596s-600s.
    View in: PubMed
    Score: 0.012
  105. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.